RAS Mutations Testing Guidelines | Find KRAS G12C
RAS mutation status is important to informing clinical decisions throughout the course of disease1,2

Guidelines recommend testing for RAS mutations—like KRAS G12C—at diagnosis of mCRC

Common CRC biomarkers, such as RAS mutations, BRAF mutations, HER2 mutations, and tumor-sidedness, may be of prognostic or predictive value3

  • Testing for RAS early and documenting mutant variants, like KRAS G12C, could be beneficial for future reference and may eliminate the need for another biopsy3,4
NCCN Clinical Guidelines, ASCP/CAP/AMT/ASCO Guidelines, ESMO Guidelines NCCN Clinical Guidelines ASCP/CAP/AMT/ASCO Guidelines ESMO Guidelines
guidelines chart NCCN Clinical Guidelines ASCP/CAP/AMT/ASCO Guidelines ESMO Guidelines

*Testing can be performed on formalin-fixed paraffin-embedded tissue or blood-based assay.5,8

The KRAS G12C variant may be reported in biomarker test results

  • KRAS panel include KRAS, as well as its variant KRAS G12C

    Comprehensive RAS panels include KRAS and its variant subtypes, including KRAS G12C9

  • Reports may vary in what level of detail is provided

    Reports may vary in what level of data is provided

  • In 2l+mCRC, knowing a patient's biomarker history is important

    In 2L+ mCRC, knowing a patient’s biomarker history is important, as tailoring next steps may be warranted6,10,11

Look deeper at RAS panel results to discover the KRAS G12C status of your mCRC patients and ensure results are accessible to help inform clinical decisions

1L, first line; 2L, second line; AMP, Association for Molecular Pathology; ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; BRAF, proto-oncogene B-Raf; CAP, College of American Pathologists; EGFR, epidermal growth factor receptor; ESMO, European Society for Medical Oncology; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; NCCN, National Comprehensive Cancer Network; NRAS, neuroblastoma rat sarcoma; RAS, rat sarcoma.

References: 1. Biller LH, et al. JAMA. 2021;325(7):669-685. 2. Cervantes A, et al. Ann Oncol. 2023;34(1):10-32. 3. Patel JN, et al. J Pers Med. 2019;9(1):3. 4. Taieb J, et al. Drugs. 2019;79(13):1375-1394. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer v.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 25, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 6. Sepulveda AR, et al. J Mol Diagn. 2017;19(2):187-225. 7. ESMO Metastatic Colorectal Cancer Living Guideline. https://www.esmo.org/living-guidelines/esmo-metastatic-colorectal-cancer-living-guideline/diagnosis/article/diagnosis-pathology-and-molecular-biology. Accessed July 28, 2023. 8. NCCN Rectal. 9. Roche Diagnostics. https://diagnostics.roche.com/us/en/products/params/cobas-kras-mutation-test.html. Accessed June 9, 2023. 10. Conroy M, et al. Cancer Drug Resist. 2021;4(3):543-558. 11. Fakih M, et al. Oncologist. 2022;27(8):663-674.